Dear Molecular Imaging Insider,
This edition of the Insider has a wealth of molecular imaging information to share. PET is at the forefront of recent research, with a study from the University of Michigan Health System finding that PET demonstrates "excellent diagnostic capabilities" in detecting coronary artery disease.
The modality also appears to be superior to anatomical imaging using multidetector CT angiography or MR angiography. More details are available in this edition's Insider Exclusive.
The European Congress of Radiology (ECR) recently concluded its annual conference, with one of the meeting's highlights a report by Italian researchers that found fused whole-body PET/CT to be significantly more accurate than whole-body 3-tesla MRI for primary tumor staging. The findings are quite enlightening, as they compared the quality of whole-body FDG-PET/CT images to CT images alone, CT and PET images viewed side by side, and whole-body 3-tesla MR images.
Also featured in this edition of the Insider is a report on the advantages of using FDG-PET/CT for staging and treatment planning of patients with head and neck carcinoma. Click here to read about PET's prowess in providing precise information on tumor localization and assessing nodal and metastatic progress.
In other recent noteworthy events, the new ownership of Bristol-Myers Squibb Medical Imaging has officially changed the company's name to Lantheus Medical Imaging.
Finally, the U.S. Centers for Medicare and Medicaid Services (CMS) has rendered its decision on whether to reimburse for the use of PET for several infection and inflammation indications. All the details can be found by clicking here.
Until next time, check the Molecular Imaging Digital Community daily to see what new research and clinical developments come to light.
